Skip to content

Colchicine for preventing respiratory failure in COVID-19 with fever

Colchicine for preventing respiratory failure in COVID-19 with fever: a randomized controlled trial - COLPREF

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031210579
Enrollment
240
Registered
2022-01-24
Start date
2022-01-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 COVID-19

Interventions

Colchicine 0.5 mg tablets for 6 days or until the date of discharge. When oxygen is started, colchicine is discontinued. Age = 60 Day 1-2: 3 tablets a day Day 3-6: 2 tablets a day Age >=70 years old o
D003078
Colchicine

Sponsors

Yokogawa Naoto
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Positive SARS-CoV-2 test (confirmed by antigen test or nucleic acid detection test using samples collected within 2 weeks before eligibility evaluation) 2) After 4 days from the onset ( If the onset date is unknown, the SARS-CoV-2 test date will be used. ) 3) High fever (38.0 degrees or higher) within 24 hours before inclusion (body temperature may be confirmed by the patient's fever record or accommodation facility record). 4) The age at the time of obtaining consent is 18 to 84 years old 5) Those who understand the contents of the clinical trial and can obtain written consent to participate in the trial.

Exclusion criteria

Exclusion criteria: 1) Those who require oxygen (room oxygen saturation of 93% or less ) 2) Those who do not agree to treatment in hospital 3) Those who are taking colchicine 4) Those who are taking 10 mg or more of prednisolone daily (or equivalent dose of other glucocorticoids) 5) Use of glucocorticoids (orally or intravenously) within the past week. 6) Sleep apnea syndrome or suspected sleep apnea syndrome 7) Severe diarrhea 8) Use of CYP3A4 inhibitor or P-glycoprotein inhibitor 9) Liver dysfunction AST or ALT exceeds 5 times the upper limit of normal value 10) Renal dysfunction eGFR less than 30mL / min / 1.73m2 11) Patients with a history of hypersensitivity to the ingredients of this drug 12) Pregnant women or women who may be pregnant at the interview

Design outcomes

Primary

MeasureTime frame
Use of oxygen (for 12 hours or longer) during admission or by Day 28

Secondary

MeasureTime frame
Oxygen-free survival at Day 7 One category improvement from baseline using 7-point ordinal scale on Day 7 Two category improvement from baseline using 7-point ordinal scale on Day 7 Duration of fever Duration of admission Death at discharge or Day 28

Contacts

Public ContactNaoto Yokogawa
yokogawan@aol.com+81-42-323-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026